Jiangsu Hengrui Secures NMPA Approvals for Trastuzumab Rezetecan, Famitinib and HR20013
China’s Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received separate marketing...
NMPA Approves Mabwell’s 8MW0511 for Febrile Neutropenia Prevention
China’s National Medical Products Administration (NMPA) has approved Mabwell (Shanghai) Bioscience Co., Ltd’s (SHA: 688062)...
Hinova’s Deutenzalutamide Approved for Metastatic Prostate Cancer in China
Chengdu-based biotech Hinova Pharmaceuticals Inc. (SHA: 688302) announced that the New Drug Application (NDA) for...
Sino Biopharmaceutical’s TQB2868 Shows Strong Results in Phase II Pancreatic Cancer Trial
China-based Sino Biopharmaceutical Ltd (HKG: 1177) presented data from its Phase II clinical trial (TQB2868-ALTN-II-01)...
Hansoh Pharma Gains NMPA Clinical Approvals for HS-10510, HS-10542, and HS-20118
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that it has received separate clinical...
Genor Biopharma Gains NMPA Approval for CDK4/6 Inhibitor Lerociclib in China
China’s Genor Biopharma Co., Ltd (HKG: 6998) announced that it has received marketing clearance from...
Astellas Pharma Licenses Evopoint’s CLDN18.2 ADC for Global Development
Japan-based Astellas Pharma Inc. (TYO: 4503) has entered into a licensing agreement with China-headquartered Evopoint...
Danaher Partners with AstraZeneca to Advance Precision Medicine
US-based science and tech services giant Danaher Corporation (NYSE: DHR) announced a strategic partnership with...
Innovent Biologics Doses First Patient in Phase III Psoriasis Trial for Picankibart
China-based Innovent Biologics, Inc. (HKG: 1801) announced the first subject dosing in a Phase III...
GSK Halts PIVOT-PO Trial Early as Tebipenem HBr Meets Efficacy Targets for cUTI
UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) announced the early termination of the pivotal Phase...
Amoytop Biotech Wins NMPA Approval for Weekly Inpegsomatropin in Pediatric Growth Deficiency
Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) announced that it has received marketing approval from...
Regend Therapeutics Gains NMPA Approval for Phase I/II Study of REGEND003 in Diabetes-Related CKD
Suzhou-based stem cell therapy specialist Regend Therapeutics announced that it has received approval from China’s...
Ganzhou Hemay Pharma Files for HK IPO with SDIC Securities Sponsorship
China-based Ganzhou Hemay Pharmaceutical Co., Ltd. has filed for an initial public offering (IPO) with...
GeneMind Biosciences Closes RMB 280 Million Series C+ Round to Fuel DNA Sequencer Innovation
Shenzhen-based DNA sequencer specialist GeneMind Biosciences Co., Ltd. has reportedly secured RMB 280 million (USD...
Abbott Laboratories Receives FDA Approval for Tendyne TMVR System
US-based medical device giant Abbott Laboratories (NYSE: ABT) announced that it has received marketing approval...
AusperBio Secures $50M in Oversubscribed Series B+ Round to Advance Hepatitis B Therapy
Sino-US liver therapy developer AusperBio announced the successful closing of an oversubscribed Series B+ financing...
BMS Gains European Approval for Opdivo Subcutaneous Formulation
Bristol-Myers Squibb (BMS; NYSE: BMY) announced that the European Commission (EC) has granted approval to...
Novartis’ Fabhalta Approved for Previously Treated PNH Patients in China
The China unit of Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that the National Medical...
InnoCare Pharma Gains NMPA Clinical Approval for BCL2 Inhibitor ICP-248
Beijing-headquartered biotech company InnoCare Pharma (HKG: 9969, SHA: 688428) announced that it has received clinical...
Fosun Pharma and Jiuyuan Gene Partner to Commercialize Biologics in Global Markets
Chinese pharmaceutical firms Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196; HKG: 2196) and Hangzhou...